4CMenB vaccine

02/14/2016 - "Based on immunological evidence, it is expected that Bexsero provides protection against this rare but very serious infection. "
08/01/2023 - "It is worth noting that the 4CMenB vaccine appears to confer some protection against gonococcal infection, which would be a considerable added value for adolescents. "
02/18/2012 - "On the basis of immunogenicity responses this study provides evidence for an adolescent 4CMenB vaccine schedule of two doses, 1-6 months apart, to provide protection against meningococcal B infection. "
05/01/2015 - "Outbreaks of meningococcal B infection and the 4CMenB vaccine: historical and future perspectives."
01/01/2014 - "Even if the cross-immunity of 4CMenB vaccine and gonorrhea is only 20%, the reduction in gonorrhea infections and associated costs would be substantial. "

01/01/2021 - "In addition to protecting against invasive meningococcal disease, emerging evidence suggests the 4CMenB vaccine may also be effective against gonorrhoea due to genetic similarities between Neisseria meningitidis and Neisseria gonorrhoeae. "
01/01/2017 - "The aim of this study was to estimate the strain coverage of the 4CMenB vaccine in Portugal in order to support health policies for prevention and control of meningococcal disease. "
11/01/2014 - "Published studies on the risk of secondary meningococcal infections were used to estimate the numbers needed to vaccinate (NNV) with Bexsero(®) to prevent a secondary case in household and educational settings. "
01/01/2022 - "4CMenB vaccine shows sustained effectiveness against serogroup B meningococcal disease 2 years after introduction in infants and adolescents, and moderate effectiveness against gonorrhoea in adolescents. "
01/01/2022 - "Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study."

01/01/2023 - "An open-label randomised controlled trial evaluating the efficacy of a meningococcal serogroup B (4CMenB) vaccine on Neisseria gonorrhoeae infection in gay and bisexual men: the MenGO study protocol."
01/01/2023 - "We assessed the vaccination effectiveness (VE) of multicomponent meningococcal serogroup B (4CMenB) vaccine against gonorrhea among people living with HIV (PLWH) with a previous diagnosis of sexually transmitted infection. "
01/01/2014 - "Even if the cross-immunity of 4CMenB vaccine and gonorrhea is only 20%, the reduction in gonorrhea infections and associated costs would be substantial. "

01/01/2017 - "Immunization with the 4CMenB vaccine elicits a robust humoral response that correlates with protection against invasive challenge but not with prevention of asymptomatic colonization. "

10/09/2014 - "Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study."
06/01/2019 - "Do HCWs adequately know about meningitis and 4CMenB vaccine and recommend its use to parents? "
07/21/2018 - "With new vaccines such as Shingrix targeting Shingles and Bexsero for Meningitis B, licensed in recent years, today's population can be protected from more infectious diseases than ever before. "
04/01/2015 - "Palbociclib (Ibrance) for breast cancer, secukinumab (Cosentyx) for plaque psoriasis, meningococcal group B vaccine (Bexsero) to help prevent meningitis, and lenvatinib (Lenvima) for differentiated thyroid cancer. "